Specialised Therapeutics has officially launched neratinib (marketed as NERLYNX) in Thailand, expanding treatment access for patients with HER2-positive breast cancer across both early-stage and metastatic settings. The oral tyrosine kinase inhibitor was approved by the Thai Food and Drug Administration in December 2024 for two distinct indications: as an extended adjuvant treatment for hormone receptor-positive (HR+) HER2-overexpressed early breast cancer, and in combination with capecitabine for patients with advanced or metastatic HER2-positive disease who have previously received at least two anti-HER2 regimens.

The dual-indication approval signals a critical step forward for the country’s oncology treatment landscape, particularly given the growing incidence and mortality rates associated with breast cancer in Thailand. What’s now being watched by industry analysts, oncologists, and health policy observers is whether the neratinib rollout will accelerate broader HER2 treatment sequencing adoption—and if Thailand can serve as a model for other Southeast Asian markets navigating similar post-trastuzumab gaps in extended adjuvant therapy.

What this launch reveals about post-trastuzumab therapy access in emerging Asia-Pacific markets

NERLYNX’s entry into Thailand marks more than a local regulatory milestone. It addresses a persistent unmet need in Southeast Asia’s oncology treatment protocols, where extended adjuvant HER2-targeted therapy options have remained limited, particularly for hormone receptor-positive patients with high relapse risk.

Industry observers have long noted that trastuzumab monotherapy—while foundational—does not provide long-term relapse protection in a substantial subset of HER2-positive patients, particularly those with concurrent hormone receptor positivity. Clinical data from the ExteNET trial showed that up to 26% of patients relapse after trastuzumab alone, with hormone receptor-positive patients representing a subgroup that benefits significantly from extended HER2 blockade via neratinib.

For countries like Thailand where anti-HER2 treatment sequencing is just starting to mature beyond trastuzumab and pertuzumab, the commercial availability of neratinib introduces a structurally new treatment layer. It also potentially delays progression to metastatic disease for early-stage patients, addressing the gap between HER2-positive recurrence rates and long-term survival outcomes.

What the clinical data actually shows—and where real-world results may diverge

The ExteNET Phase III study remains the key evidentiary anchor for neratinib’s extended adjuvant use. With over 2,800 participants across 41 countries, the trial showed a 27% reduction in invasive disease-free survival events with neratinib versus placebo in HER2-positive patients post-trastuzumab. In the subgroup of HR+/HER2+ patients who started treatment within 12 months of completing trastuzumab, the recurrence risk dropped by up to 42%. Central nervous system recurrence—a major clinical challenge in HER2+ breast cancer—was also reduced by nearly 60% in this subgroup.

That said, the real-world clinical uptake of neratinib has been tempered in other markets by tolerability concerns, particularly high rates of grade 3 diarrhea. In the ExteNET trial, gastrointestinal adverse events were common, though often manageable with dose titration and prophylactic loperamide. Clinicians tracking the field suggest that Thailand’s rollout success will partly hinge on physician education regarding dose adjustment protocols and proactive side effect management.

On the metastatic side, data from the NALA trial positions neratinib plus capecitabine as a post-lapatinib alternative. Although the improvement in progression-free survival was modest—an increase of 2.2 months over lapatinib plus capecitabine—treatment duration and brain metastasis delay suggest clinically relevant differentiation. Patients receiving neratinib experienced a longer median duration of response (8.5 months vs 5.6 months) and a lower cumulative incidence of CNS progression.

These findings, while nuanced, establish a differentiated niche for neratinib in the post-trastuzumab, post-T-DM1 sequencing paradigm. The question now is how payers and prescribers in Thailand will interpret these advantages relative to cost, tolerability, and real-world patient profiles.

Why this matters for HER2+ disease management in Thailand and the broader region

The significance of neratinib’s arrival in Thailand also lies in local epidemiology. Breast cancer is now the leading cancer among Thai women, accounting for over 20,000 new cases and more than 4,800 deaths annually. HER2 positivity—found in roughly one in four breast cancers—has been associated with more aggressive disease biology and poorer survival rates, particularly in resource-constrained healthcare systems where diagnostic and treatment sequencing is delayed.

Specialised Therapeutics’ Thai launch represents its first major commercial foray into the country and reflects a broader push by specialty pharma to extend Tier 1 oncology therapies into Southeast Asian markets. For context, most HER2-targeted sequencing strategies (trastuzumab, pertuzumab, T-DM1, tucatinib, etc.) are still emerging or inconsistently reimbursed in many ASEAN markets. Introducing neratinib in this setting could support efforts to normalize extended HER2 blockade in both early and metastatic care pathways.

Regulatory watchers suggest that neratinib’s dual-label approval in Thailand also offers insight into how middle-income countries may structure oncology approvals going forward. By securing approvals in both the curative-intent and palliative settings, Specialised Therapeutics has effectively doubled its potential prescriber base—while setting the stage for future regional expansion using a similar dual-indication approach.

What adoption, reimbursement, and sequencing risks could derail momentum

Despite its clinical potential, neratinib’s uptake is not guaranteed. Access challenges remain, particularly in Thailand’s two-tiered public-private healthcare system where novel therapies often face lagged reimbursement decisions and unequal provincial availability. While Specialised Therapeutics has deployed a local field team to engage oncologists and clinicians, the impact of this on actual prescribing trends remains unproven.

Pricing and formulary inclusion are likely to emerge as the next battleground. Industry analysts note that while neratinib provides a differentiated mechanism and statistically significant benefit, its cost-effectiveness relative to other HER2-targeted agents—especially when factoring in prophylaxis for adverse events—may be scrutinized during payer evaluations.

Moreover, the post-trastuzumab sequencing space has become increasingly crowded, with newer entrants like tucatinib and trastuzumab deruxtecan offering alternative options with distinct efficacy and tolerability profiles. Neratinib’s irreversible pan-HER blockade, while mechanistically appealing, must now compete in a more complex, biomarker-driven treatment algorithm that prioritizes not just efficacy, but also CNS activity, safety, and quality-of-life metrics.

For clinicians, sequencing decisions are growing more personalized—based not just on prior therapy but also on patient tolerability, resistance patterns, and access constraints. The challenge for neratinib will be maintaining relevance in both early-stage relapse prevention and late-line metastatic settings without being overshadowed by newer-generation agents.

What happens next if Thailand becomes a case study in successful HER2+ rollout

If neratinib demonstrates strong uptake in Thailand across both its approved indications, the implications may ripple across Southeast Asia. Countries such as Malaysia, Indonesia, and Vietnam are watching Thailand’s evolving oncology reimbursement models closely, particularly as cancer incidence rises across the region and international partnerships aim to bridge diagnostic and therapeutic gaps.

From a commercial standpoint, Specialised Therapeutics may leverage Thailand as a proof point to extend its portfolio across ASEAN, applying lessons from neratinib to other specialty oncology products. Puma Biotechnology’s licensing strategy also gains validation, reinforcing the viability of specialty distribution in emerging markets without the need for large in-country infrastructure.

Ultimately, Thailand’s experience with neratinib could serve as a regional case study on balancing evidence-based approvals with real-world scalability. For HER2-positive patients, the stakes are personal—but for the industry, this launch is a litmus test in how far Southeast Asia has progressed in closing the HER2+ therapy gap.

  adjuvant therapy, ExteNET trial, HER2-positive breast cancer, metastatic breast cancer, NALA trial, neratinib, NERLYNX, oncology access, Puma Biotechnology, Specialised Therapeutics, Thailand FDA